SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Med Spa Vacations Inc. – ‘10-Q’ for 9/30/22

On:  Friday, 10/21/22, at 4:18pm ET   ·   For:  9/30/22   ·   Accession #:  1640334-22-2264   ·   File #:  333-210922

Previous ‘10-Q’:  ‘10-Q’ on 7/19/22 for 6/30/22   ·   Latest ‘10-Q’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/21/22  Med Spa Vacations Inc.            10-Q        9/30/22   35:1.8M                                   Pubco Reporting … Inc/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    459K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     16K 
 3: EX-32.1     Certification -- §906 - SOA'02                      HTML     13K 
 9: R1          Cover                                               HTML     60K 
10: R2          Balance Sheets                                      HTML     79K 
11: R3          Balance Sheets (Parenthetical)                      HTML     29K 
12: R4          Statements of Operations (Unaudited)                HTML     47K 
13: R5          Statements of Stockholders Deficit (Unaudited)      HTML     53K 
14: R6          Statements of Cash Flows (Unaudited)                HTML     70K 
15: R7          Summary Of Significant Accounting Policies          HTML     17K 
16: R8          Going Concern                                       HTML     16K 
17: R9          Related Party Transactions                          HTML     43K 
18: R10         Notes Payable                                       HTML     28K 
19: R11         Commitments                                         HTML     15K 
20: R12         Subsequent Events                                   HTML     14K 
21: R13         Summary Of Significant Accounting Policies          HTML     24K 
                (Policies)                                                       
22: R14         Related Party Transactions (Tables)                 HTML     37K 
23: R15         Notes Payable (Tables)                              HTML     27K 
24: R16         Summary Of Significant Accounting Policies          HTML     15K 
                (Details Narrative)                                              
25: R17         Going Concern (Details Narrative)                   HTML     15K 
26: R18         Related Party Transactions (Details)                HTML     51K 
27: R19         Related Party Transactions (Details Narrative)      HTML     47K 
28: R20         Notes Payable (Details)                             HTML     33K 
29: R21         Notes Payable (Details Narrative)                   HTML     24K 
30: R22         Commitments (Details Narrative)                     HTML     14K 
33: XML         IDEA XML File -- Filing Summary                      XML     55K 
31: XML         XBRL Instance -- mdvp_10q_htm                        XML    420K 
32: EXCEL       IDEA Workbook of Financial Reports                  XLSX     42K 
 6: EX-101.CAL  XBRL Calculations -- mdvp-20220930_cal               XML     63K 
 8: EX-101.DEF  XBRL Definitions -- mdvp-20220930_def                XML    117K 
 5: EX-101.LAB  XBRL Labels -- mdvp-20220930_lab                     XML    341K 
 7: EX-101.PRE  XBRL Presentations -- mdvp-20220930_pre              XML    243K 
 4: EX-101.SCH  XBRL Schema -- mdvp-20220930                         XSD     70K 
34: JSON        XBRL Instance as JSON Data -- MetaLinks              140±   187K 
35: ZIP         XBRL Zipped Folder -- 0001640334-22-002264-xbrl      Zip     79K 


‘10-Q’   —   Quarterly Report

Document Table of Contents

Page (sequential)   (alphabetic) Top
 
11st Page  –  Filing Submission
"Table of Contents
"Part I -- Financial Information
"Item 1
"Financial Statements (Unaudited)
"Unaudited Balance Sheets
"Unaudited Statements of Operations
"Unaudited Statements of Stockholders' Deficit
"Unaudited Statements of Cash Flows
"Notes to the Unaudited Financial Statements
"Item 2
"Management's Discussion and Analysis of Financial Condition and Results of Operations
"Item 3
"Quantitative and Qualitative Disclosures About Market Risk
"Item 4
"Controls and Procedures
"Part Ii -- Other Information
"Legal Proceedings
"Item 1A
"Risk Factors
"Unregistered Sales of Equity Securities and Use of Proceeds
"Defaults Upon Senior Securities
"Mine Safety Disclosures
"Item 5
"Item 6
"Exhibits
"Signatures

This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C: 
 i 0001671077 i false i --12-31 i Q3 i 2022 i 0.001 i 25000000 i 0 i 0 i 0 i 0 i 0.001 i 100000000 i 10005000 i 1005500000016710772022-01-012022-09-300001671077mdvp:BenchmarkConsultingAgreementMember2022-01-012022-09-300001671077mdvp:BenchmarkConsultingAgreementMember2018-06-012018-06-180001671077mdvp:SeptemberOneTwoThousandTwentyTwoMember2022-08-312022-09-010001671077mdvp:SeptemberOneTwoThousandTwentyTwoMember2022-09-010001671077mdvp:SeptemberOneTwoThousandTwentyTwoMember2022-09-300001671077mdvp:SeptemberOneTwoThousandTwentyTwoMember2021-12-310001671077mdvp:MayTwoTwoThousandTwentyTwoMember2022-05-020001671077mdvp:MayTwoTwoThousandTwentyTwoMember2022-05-012022-05-020001671077mdvp:MayTwoTwoThousandTwentyTwoMember2021-12-310001671077mdvp:MayTwoTwoThousandTwentyTwoMember2022-09-300001671077mdvp:FebruaryOneTwoTwoThousandTwentyOneMember2021-02-012021-02-120001671077mdvp:FebruaryOneTwoTwoThousandTwentyOneMember2021-02-120001671077mdvp:FebruaryOneTwoTwoThousandTwentyOneMember2022-09-300001671077mdvp:FebruaryOneTwoTwoThousandTwentyOneMember2021-12-310001671077us-gaap:InterestExpenseMember2022-01-012022-09-300001671077us-gaap:InterestExpenseMember2021-01-012021-09-300001671077mdvp:MedSpaVacationsIncMember2022-01-012022-09-300001671077mdvp:MedSpaVacationsIncMember2021-01-012021-09-300001671077mdvp:FormerOfficerAndDirectorMember2022-01-012022-09-300001671077mdvp:SoleDirectorAndOfficerMember2022-01-012022-09-300001671077mdvp:SoleDirectorAndOfficerMember2021-01-012021-09-300001671077mdvp:SoleDirectorAndOfficerMember2021-09-300001671077mdvp:SoleDirectorAndOfficerMember2022-07-110001671077mdvp:SoleDirectorAndOfficerMember2022-07-012022-07-110001671077mdvp:SoleDirectorAndOfficerMember2022-09-300001671077mdvp:ShareholderFourMember2021-11-012021-11-290001671077mdvp:ShareholderThreeMember2021-10-012021-10-270001671077mdvp:ShareholderTwoMember2021-09-012021-09-280001671077mdvp:ShareholderOneMember2021-05-012021-05-100001671077mdvp:ShareholderFourMember2021-11-290001671077mdvp:ShareholderThreeMember2021-10-270001671077mdvp:ShareholderTwoMember2021-09-280001671077mdvp:ShareholderOneMember2021-05-100001671077mdvp:ShareholderSevenMember2022-02-282022-03-010001671077mdvp:ShareholderSixMember2022-02-282022-03-010001671077mdvp:ShareholderFiveMember2022-01-012022-01-180001671077mdvp:ShareholderSevenMember2022-03-010001671077mdvp:ShareholderSixMember2022-03-010001671077mdvp:ShareholderOneMember2022-09-300001671077mdvp:ShareholderSevenMember2021-12-310001671077mdvp:ShareholderFiveMember2022-01-180001671077mdvp:ShareholderSixMember2022-09-300001671077mdvp:ShareholderFiveMember2021-12-310001671077mdvp:ShareholderThreeMember2021-12-310001671077mdvp:ShareholderSevenMember2022-09-300001671077mdvp:ShareholderSixMember2021-12-310001671077mdvp:ShareholderFiveMember2022-09-300001671077mdvp:ShareholderFourMember2021-12-310001671077mdvp:ShareholderFourMember2022-09-300001671077mdvp:ShareholderThreeMember2022-09-300001671077mdvp:ShareholderTwoMember2021-12-310001671077mdvp:ShareholderTwoMember2022-09-300001671077mdvp:ShareholderOneMember2021-12-310001671077us-gaap:RetainedEarningsMember2022-09-300001671077us-gaap:AdditionalPaidInCapitalMember2022-09-300001671077us-gaap:CommonStockMember2022-09-300001671077us-gaap:RetainedEarningsMember2022-07-012022-09-300001671077us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001671077us-gaap:CommonStockMember2022-07-012022-09-3000016710772022-06-300001671077us-gaap:RetainedEarningsMember2022-06-300001671077us-gaap:AdditionalPaidInCapitalMember2022-06-300001671077us-gaap:CommonStockMember2022-06-3000016710772022-04-012022-06-300001671077us-gaap:RetainedEarningsMember2022-04-012022-06-300001671077us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001671077us-gaap:CommonStockMember2022-04-012022-06-3000016710772022-03-310001671077us-gaap:RetainedEarningsMember2022-03-310001671077us-gaap:AdditionalPaidInCapitalMember2022-03-310001671077us-gaap:CommonStockMember2022-03-3100016710772022-01-012022-03-310001671077us-gaap:RetainedEarningsMember2022-01-012022-03-310001671077us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001671077us-gaap:CommonStockMember2022-01-012022-03-310001671077us-gaap:RetainedEarningsMember2021-12-310001671077us-gaap:AdditionalPaidInCapitalMember2021-12-310001671077us-gaap:CommonStockMember2021-12-3100016710772021-09-300001671077us-gaap:RetainedEarningsMember2021-09-300001671077us-gaap:AdditionalPaidInCapitalMember2021-09-300001671077us-gaap:CommonStockMember2021-09-300001671077us-gaap:RetainedEarningsMember2021-07-012021-09-300001671077us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001671077us-gaap:CommonStockMember2021-07-012021-09-3000016710772021-06-300001671077us-gaap:RetainedEarningsMember2021-06-300001671077us-gaap:AdditionalPaidInCapitalMember2021-06-300001671077us-gaap:CommonStockMember2021-06-3000016710772021-04-012021-06-300001671077us-gaap:RetainedEarningsMember2021-04-012021-06-300001671077us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001671077us-gaap:CommonStockMember2021-04-012021-06-3000016710772021-03-310001671077us-gaap:RetainedEarningsMember2021-03-310001671077us-gaap:AdditionalPaidInCapitalMember2021-03-310001671077us-gaap:CommonStockMember2021-03-3100016710772021-01-012021-03-310001671077us-gaap:RetainedEarningsMember2021-01-012021-03-310001671077us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001671077us-gaap:CommonStockMember2021-01-012021-03-3100016710772020-12-310001671077us-gaap:RetainedEarningsMember2020-12-310001671077us-gaap:AdditionalPaidInCapitalMember2020-12-310001671077us-gaap:CommonStockMember2020-12-3100016710772021-01-012021-09-3000016710772021-07-012021-09-3000016710772022-07-012022-09-3000016710772021-12-3100016710772022-09-3000016710772022-10-21iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM  i 10-Q

 

(Mark One)

 

 i  

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

For the fiscal year ended:  i September 30, 2022

 

 or

 i 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

For the transition period from _______________ to _______________

 

Commission file number:  i 333-210922

 

 i MED SPA VACATIONS INC.

(Exact name of registrant as specified in its charter)

 

 i Nevada

 

 i 47-5268172

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

 i 500 W. 5th Street, Suite 800 i PMB #59

 i Winston Salem i NC  i 27101

(Address of principal executive offices)

 

( i 845 i 548-3280

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

None

N/A

N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  i Yes ☒ No ☐

 

(Note: The registrant is a voluntary filer of reports under Section 13 or 15(d) of the Securities Exchange Act of 1934; the registrant has filed during the preceding 12 months all reports it would have been required to file by Section 13 or 15(d) of the Securities Exchange Act of 1934 if the registrant had been subject to one of such Sections.)

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  i Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

 i Non-accelerated Filer

Smaller reporting company

 i 

 

 

Emerging growth company

 i 

 

If an emerging growth company, indicate by check mark if this registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  i  No ☐

 

As of October 21, 2022, there were  i 10,055,000 shares of the registrant’s common stock, par value $0.001 per share, issued and outstanding.

 

 

 

 

MED SPA VACATIONS INC.

 

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022

 

TABLE OF CONTENTS

 

 

 

 

PAGE

 

 

 

 

 

 

 

PART I - FINANCIAL INFORMATION

 

 

 

 

 

 

 

 

Item 1.

Financial Statements (Unaudited)

 

F-2

 

 

 

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

3

 

 

 

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

7

 

 

 

 

 

 

Item 4.

Controls and Procedures

 

7

 

 

 

 

 

 

 

PART II - OTHER INFORMATION

 

 

 

 

 

 

 

 

Item 1.

Legal Proceedings

 

8

 

 

 

 

 

 

Item 1A.

Risk Factors

 

8

 

 

 

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

8

 

 

 

 

 

 

Item 3.

Defaults Upon Senior Securities

 

8

 

 

 

 

 

 

Item 4.

Mine Safety Disclosures

 

8

 

 

 

 

 

 

Item 5.

Other Information

 

8

 

 

 

 

 

 

Item 6.

Exhibits

 

9

 

 

 

 

 

 

 

SIGNATURES

 

10

 

 

 

Table of Contents

 

MED SPA VACATIONS, INC.

 

INDEX TO AUDITED FINANCIAL STATEMENTS

FOR THE PERIOD ENDED SEPTEMBER 30, 2022

 

 

Page

 

 

 

 

 

Unaudited Balance Sheets

 

F-2

 

 

 

 

 

Unaudited Statements of Operations

 

F-3

 

 

 

 

 

Unaudited Statements of Stockholders’ Deficit

 

F-4

 

 

 

 

 

Unaudited Statements of Cash Flows

 

F-5

 

 

 

 

 

Notes to the Unaudited Financial Statements

 

F-6

 

 

 
F-1

Table of Contents

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

 MED SPA VACATIONS INC.

Balance Sheets

(Unaudited)

 

 

 

September 30,

 

 

December 31,

 

 

 

2022

 

 

2021

 

ASSETS

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash

 

$ i 17,028

 

 

$ i 2,266

 

Total Current Assets

 

 

 i 17,028

 

 

 

 i 2,266

 

 

 

 

 

 

 

 

 

 

Total Assets

 

$ i 17,028

 

 

$ i 2,266

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$ i 2,213

 

 

$ i 6

 

Accrued interest - related party

 

 

 i -

 

 

 

 i 1,196

 

Note payable - related party

 

 

 i -

 

 

 

 i 128,750

 

Note payable

 

 

 i 235,000

 

 

 

 i -

 

Total Current Liabilities

 

 

 i 237,213

 

 

 

 i 129,952

 

 

 

 

 

 

 

 

 

 

Total Liabilities

 

 

 i 237,213

 

 

 

 i 129,952

 

 

 

 

 

 

 

 

 

 

Stockholders' Deficit:

 

 

 

 

 

 

 

 

Preferred stock, $ i 0.001 par value,  i 25,000,000 shares authorized, no shares issued and outstanding

 

 

 i -

 

 

 

 i -

 

Common stock, $ i 0.001 par value,  i 100,000,000 shares authorized,  i 10,055,000 shares and  i 10,005,000 shares issued and outstanding, respectively

 

 

 i 10,055

 

 

 

 i 10,005

 

Additional paid-in capital

 

 

 i 396,746

 

 

 

 i 395,296

 

Accumulated deficit

 

 

( i 626,986)

 

 

( i 532,987)

Total Stockholders' Deficit

 

 

( i 220,185)

 

 

( i 127,686)

Total Liabilities and Stockholders' Deficit

 

$ i 17,028

 

 

$ i 2,266

 

 

 The accompanying notes to the unaudited financial statements are an integral part of these statements.

 

 
F-2

Table of Contents

 

MED SPA VACATIONS INC.

Statements of Operations

(Unaudited)

 

 

 

 Three Months Ended

 

 

 Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

$ i 891

 

 

$ i 770

 

 

$ i 2,775

 

 

$ i 2,211

 

Management compensation - related party

 

 

 i 4,500

 

 

 

 i 3,000

 

 

 

 i 10,500

 

 

 

 i 6,000

 

Professional fees

 

 

 i 21,712

 

 

 

 i 19,421

 

 

 

 i 72,135

 

 

 

 i 126,037

 

Total Operating Expenses

 

 

 i 27,103

 

 

 

 i 23,191

 

 

 

 i 85,410

 

 

 

 i 134,248

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

( i 27,103)

 

 

( i 23,191)

 

 

( i 85,410)

 

 

( i 134,248)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

( i 3,347)

 

 

 i -

 

 

 

( i 5,432)

 

 

( i 2,250)

Interest expense - related party

 

 

 i -

 

 

 

( i 1,518)

 

 

( i 3,157)

 

 

( i 2,356)

Total Other Expense

 

 

( i 3,347)

 

 

( i 1,518)

 

 

( i 8,589)

 

 

( i 4,606)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

$( i 30,450)

 

$( i 24,709)

 

$( i 93,999)

 

$( i 138,854)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per common share: basic and diluted

 

$( i 0.00)

 

$( i 0.00)

 

$( i 0.01)

 

$( i 0.01)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding: basic and diluted

 

 

 i 10,049,022

 

 

 

 i 10,005,000

 

 

 

 i 10,019,835

 

 

 

 i 10,577,967

 

 

The accompanying notes to the unaudited financial statements are an integral part of these statements.

 

 
F-3

Table of Contents

 

MED SPA VACATIONS INC.

Statements of Stockholders’ Deficit

(Unaudited)

 

For the Nine Months Ended September 30, 2022

 

 

 

 

 

 

Additional

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Accumulated

 

 

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Deficit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - December 30, 2021

 

 

 i 10,005,000

 

 

$ i 10,005

 

 

$ i 395,296

 

 

$( i 532,987)

 

$( i 127,686)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

-

 

 

 

 i -

 

 

 

 i -

 

 

 

( i 35,984)

 

 

( i 35,984)

Balance - March 31, 2022

 

 

 i 10,005,000

 

 

 

 i 10,005

 

 

 

 i 395,296

 

 

 

( i 568,971)

 

 

( i 163,670)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

-

 

 

 

 i -

 

 

 

 i -

 

 

 

( i 27,565)

 

 

( i 27,565)

Balance - June 30, 2022

 

 

 i 10,005,000

 

 

 

 i 10,005

 

 

 

 i 395,296

 

 

 

( i 596,536)

 

 

( i 191,235)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance common stock based on compensation - related party

 

 

 i 50,000

 

 

 

 i 50

 

 

 

 i 1,450

 

 

 

 i -

 

 

 

 i 1,500

 

Net loss

 

 

-

 

 

 

 i -

 

 

 

 i -

 

 

 

( i 30,450)

 

 

( i 30,450)

Balance - September 30, 2022

 

 

 i 10,055,000

 

 

$ i 10,055

 

 

$ i 396,746

 

 

$( i 626,986)

 

$( i 220,185)

 

For the Nine Months Ended September 30, 2021

 

 

 

 

 

 

Additional

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Accumulated

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Deficit

 

Balance - December 31, 2020

 

 

 i 14,350,000

 

 

$ i 14,350

 

 

$ i 272,445

 

 

$( i 367,781)

 

$( i 80,986)

Cancellation of common stock

 

 

( i 4,345,000)

 

 

( i 4,345)

 

 

 i 4,345

 

 

 

 i -

 

 

 

 i -

 

Debt forgiveness by related party

 

 

-

 

 

 

 i -

 

 

 

 i 118,506

 

 

 

 i -

 

 

 

 i 118,506

 

Net loss

 

 

-

 

 

 

 i -

 

 

 

 i -

 

 

 

( i 78,264)

 

 

( i 78,264)

Balance - March 31, 2021

 

 

 i 10,005,000

 

 

 

 i 10,005

 

 

 

 i 395,296

 

 

 

( i 446,045)

 

 

( i 40,744)

Net loss

 

 

-

 

 

 

 i -

 

 

 

 i -

 

 

 

( i 35,881)

 

 

( i 35,881)

Balance - June 30, 2021

 

 

 i 10,005,000

 

 

 

 i 10,005

 

 

 

 i 395,296

 

 

 

( i 481,926)

 

 

( i 76,625)

Net loss

 

 

-

 

 

 

 i -

 

 

 

 i -

 

 

 

( i 24,709)

 

 

( i 24,709)

Balance - September 30, 2021

 

 

 i 10,005,000

 

 

$ i 10,005

 

 

$ i 395,296

 

 

$( i 506,635)

 

$( i 101,334)

 

The accompanying notes to the unaudited financial statements are an integral part of these statements.

 

 
F-4

Table of Contents

 

MED SPA VACATIONS INC.

Statements of Cash Flow

(Unaudited)

 

 

 

 Nine Months Ended

 

 

 

September 30,

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

Cash Flows from Operating Activities

 

 

 

 

 

 

Net loss

 

$( i 93,999)

 

$( i 138,854)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Stock based compensation- related party

 

 

 i 1,500

 

 

 

 i -

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Expenses paid by related party

 

 

 i -

 

 

 

 i 74,184

 

Accounts payable and accrued liabilities

 

 

 i 2,207

 

 

 

( i 36,157)

Accrued note payable interest - related party

 

 

( i 1,196)

 

 

 i 856

 

Net cash used in operating activities

 

 

( i 91,488)

 

 

( i 99,971)

 

 

 

 

 

 

 

 

 

Cash Flows from Financing Activities

 

 

 

 

 

 

 

 

Proceeds of promissory note payable

 

 

 i 235,000

 

 

 

 i 150,000

 

Repayment of promissory note payable

 

 

 i -

 

 

 

 i 150,000

 

Repayment of promissory note payable -related party

 

 

( i 183,250)

 

 

 i -

 

Proceeds of promissory note payable - related party

 

 

 i 54,500

 

 

 

 i 115,000

 

Net cash provided by Financing Activities

 

 

 i 106,250

 

 

 

 i 115,000

 

 

 

 

 

 

 

 

 

 

Net change in cash for period

 

 

 i 14,762

 

 

 

 i 15,029

 

Cash at beginning of period

 

 

 i 2,266

 

 

 

 i -

 

Cash at end of period

 

$ i 17,028

 

 

$ i 15,029

 

 

 

 

 

 

 

 

 

 

Supplemental Cash Flow Information

 

 

 

 

 

 

 

 

Cash paid for income taxes

 

$ i -

 

 

$ i -

 

Cash paid for interest

 

$ i 7,578

 

 

$ i 3,750

 

 

 

 

 

 

 

 

 

 

Non-Cash Investing and Financing Activities

 

 

 

 

 

 

 

 

Related party debt forgiven recorded as additional paid in capital

 

$ i -

 

 

$ i 118,506

 

Issuance of common stock for compensation -related party

 

$ i 1,500

 

 

$ i -

 

Cancellation of common stock

 

$ i -

 

 

$ i 4,345

 

 

The accompanying notes to the unaudited financial statements are an integral part of these statements.

 

 
F-5

Table of Contents

 

MED SPA VACATIONS INC.

Notes to the Unaudited Financial Statements

September 30, 2022

 

 i 

Note 1 - Summary of Significant Accounting Policies

 

Basis of Presentation of Unaudited Interim Financial Statements

 

 i 

The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2022, and the results of operations and cash flows for the periods presented. The results of operations for the period ended September 30, 2022, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited interim financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 24, 2022.

 

Use of Estimates and Assumptions

 

 i 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

 i 

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. The Company had $ i 17,028 and $ i 2,266 in cash as of September 30,2022 and December 31, 2021, respectively.

 / 

 

Reclassification

 

 i 

Certain accounts from prior periods have been reclassified to conform to the current period presentation.

 / 

 

 i 

Note 2 – Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As of September 30, 2022, the Company has reoccurring losses from operations, an accumulated deficit of $ i 626,986 and has earned no revenues. The Company intends to fund operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending December 31, 2022.

 

The ability of the Company to emerge from the early stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of its business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings.

 

These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. 

 / 

 

 
F-6

Table of Contents

 

 i 

Note 3 – Related Party Transactions

 

During the nine months ended September 30,2022 and 2021,

 

 

·

the Company’s controlling shareholder advanced to the Company an amount of $ i 0 and $ i 74,184, respectively, to pay certain expenses on behalf of the Company.

 

 

 

 

·

the Company paid $ i 2,000 management fees to the former officer and director of the Company who resigned on May 21, 2021.

 

 

 

 

·

the Company paid $ i 9,000 and $ i 4,000, respectively, management fees to the sole officer and director of the Company.

 

 

 

 

·

On June 30, 2022, the Company’s Board of Directors approved the issuance of 50,000 shares of common stock to the Company’s sole officer and director as compensation. On July 11, 2022, the  i 50,000 shares of common stock were issued. The Company evaluated 50,000 shares issued at last the Company’s stock transaction of $ i 0.03 per share for amount of $ i 1,500.

 

Notes payable – Related Parties

 

The components of notes payable to related parties as of September 30,2022 and December 31,2021 were as follows:

 

 i 

Relationship

 

Issuance

date

 

Principal

Amount

 

 

   Maturity

date

 

Interest

rate

 

 

September 30,

2022

 

 

December 31,

2021

 

Shareholder

 

May 10, 2021

 

$ i 100,000

 

 

 i May 9, 2022

 

 

 i 6%

 

$ i -

 

 

$ i 100,000

 

Shareholder

 

September 28, 2021

 

$ i 15,000

 

 

 i September 27, 2022

 

 

 i 6%

 

 

 i -

 

 

 

 i 15,000

 

Shareholder

 

October 27, 2021

 

$ i 5,250

 

 

 i October 26, 2022

 

 

 i 6%

 

 

 i -

 

 

 

 i 5,250

 

Shareholder

 

November 29, 2022

 

$ i 8,500

 

 

 i November 29, 2022

 

 

 i 6%

 

 

 i -

 

 

 

 i 8,500

 

Shareholder

 

January 18, 2022

 

$ i 15,000

 

 

 i January 18, 2023

 

 

 i 6%

 

 

 i -

 

 

 

 i -

 

Shareholder

 

March 1, 2022

 

$ i 19,500

 

 

 i March 1, 2023

 

 

 i 6%

 

 

 i -

 

 

 

 i -

 

Shareholder

 

March 1, 2022

 

$ i 20,000

 

 

 i March 1, 2023

 

 

 i 6%

 

 

 i -

 

 

 

 i -

 

Total notes payable - related party

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 i -

 

 

 

 i 128,750

 

Current portion

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 i -

 

 

 

( i 128,750)

Long-term portion

 

 

 

 

 

 

 

 

 

 

 

 

 

$ i -

 

 

$ i -

 

 / 

 

During the nine months ended September 30, 2022 and 2021, the Company received $ i 54,500 and $ i 115,000 loans and repaid the outstanding promissory notes of $ i 183,259 and $ i 0, respectively.

 

During the nine months ended September 30, 2022, the Company recorded interest expense of $ i 3,157 and repaid $ i 4,353 of interest. During the nine months ended September 30, 2021, the Company recorded interest expense of $ i 2,356 and repaid $ i 1,500 of interest.

 

As of September 30, 2022 and December 31, 2021, the outstanding balances of promissory notes and accrued interest were $ i 0 and $ i 0 and $ i 128,750 and $ i 1,196, respectively.

 / 

 

 
F-7

Table of Contents

 

 i 

Note 4 – Notes Payable

 

The components of notes payable as of September 30, 2022 and December 31, 2021 were as follows:

 

 i 

Issuance date

 

Principal

Amount

 

 

   Maturity

date

 

Interest

rate

 

 

September 30,

2022

 

 

December 31,

2021

 

February 12, 2021

 

$ i 150,000

 

 

 i February 11, 2022

 

 

 i 6%

 

$ i -

 

 

$ i -

 

May 2, 2022

 

$ i 215,000

 

 

 i May 1, 2023

 

 

 i 6%

 

 

 i 215,000

 

 

 

 i -

 

September 1, 2022

 

$ i 20,000

 

 

 i August 31, 2023

 

 

 i 6%

 

 

 i 20,000

 

 

 

 i -

 

Total notes payable

 

 

 

 

 

 

 

 

 

 

 

 

 i 235,000

 

 

$ i -

 

Current portion

 

 

 

 

 

 

 

 

 

 

 

 

( i 235,000)

 

 

 i -

 

Long-term portion

 

 

 

 

 

 

 

 

 

 

 

$ i -

 

 

$ i -

 

 / 

 

During the nine months ended September 30, 2022 and 2021, the Company received $ i 235,000 and $ i 150,000 in loans and repaid the outstanding promissory notes of $ i 0 and $ i 150,000, respectively.

 

During the nine months ended September 30, 2022, the Company recorded interest expense of $ i 5,432 and repaid $ i 3,225 of interest. During the nine months ended September 30, 2021, the Company recorded interest expense of $ i 2,250 and repaid $ i 2,250 of interest. As of September 30, 2022, the outstanding balances of promissory notes and accrued interest were $ i 235,000 and $ i 2,207, respectively.

 / 

 

 i 

Note 5 – Commitments

 

On June 18, 2021, the Company entered into a consulting agreement (the “Benchmark Consulting Agreement”) with Benchmark Capital, LLC, a New Jersey limited liability company (“Benchmark”), effective as of July 1, 2021. Pursuant to the Benchmark Consulting Agreement, Benchmark will assist the Company in connection with all fillings required by the Company to be made with the SEC, for a consulting fee of $ i 2,500 per month. The Benchmark Consulting Agreement can be terminated by either party, at any time, upon 30 days’ prior written notice. During the nine months ended September 30, 2022, the Company incurred and paid consulting fees of $ i 22,500.

 / 

 

 i 

Note 6– Subsequent Events

 

Management has evaluated subsequent events through the date these financial statements were available to be issued. Based on our evaluation no material events have occurred that require disclosure.

 

 
F-8

Table of Contents

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve risks and uncertainties, including, among other things, statements regarding our business strategy, future revenues and anticipated costs and expenses. Such forward-looking statements include, among others, those statements including the words “expects,” “anticipates,” “intends,” “believes” and similar language. Our actual results may differ significantly from those projected in the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed herein. You should carefully review the risks described herein and in other documents we file from time to time with the Securities and Exchange Commission. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. We undertake no obligation to publicly release any revisions to the forward-looking statements or reflect events or circumstances after the date of this document.

 

Although we believe that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements.

 

All references in this Form 10-Q to the “Company,” “we,” “us,” or “our,” are to Med Spa Vacations Inc.

 

General Overview

 

We were incorporated in the State of Nevada on October 5, 2015 to develop a business that specialized in marketing health and wellness vacations to both individuals and corporate groups looking to revitalize and develop a fuller day-to-day life. Because we were not able to raise sufficient capital to execute our original business plan, we discontinued that line of business. Our office address is 500 W. 5th Street, Suite 800, PMB #59, Winston Salem, NC 27101.

 

The Company is a shell company, as that term is defined in Rule 12b-2 of the Exchange Act of 1934, as amended. The Company is seeking a business combination with a private entity whose business would present an opportunity for its shareholders. No specific assets or businesses have been definitively identified and there is no certainty that any such assets or business will be identified or that any transactions will be consummated.

 

On February 4, 2021, our controlling stockholder Kynson Health Limited, a company incorporated and existing under the law of the British Virgin Islands (“Kynson Health”), closed stock purchase and sale transactions pursuant to which Kynson Health sold an aggregate of 9,985,329 restricted shares (the “Shares”) of the Company’s common stock, $0.001 par value per share, to eleven purchasers at a purchase price of $0.030044 per share, or an aggregate purchase price of $299,998.60 (the “Share Sale Transaction”). The Shares represented approximately 99.8% of the Company’s issued and outstanding shares of common stock as of the date of the closing of the Share Sale Transaction, taking into account the share cancellations further described below.

 

On February 4, 2021, in connection with, and as a condition to, the consummation of the Share Sale Transaction, eleven shareholders of the Company returned an aggregate of 4,345,000 shares of the Company’s common stock to the Company for cancellation, in consideration for $0.001 per share. Said shares were returned to the Company’s number of authorized and unissued shares of common stock.

 

We have no revenues and limited cash on hand. We have sustained losses since inception. We have never declared bankruptcy, been in receivership, or involved in any kind of legal proceeding.

 

Results of Operations

 

Three Months Ended September 30, 2022, Compared to Three Months Ended September 30, 2021

 

Our results of operations for the three months ended September 30, 2022 and 2021 are summarized below:

 

 

 

 Three Months Ended

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

2022

 

 

2021

 

 

Change

 

Revenue

 

$-

 

 

$-

 

 

$-

 

Operating expenses

 

 

27,103

 

 

 

23,191

 

 

 

3,912

 

Other expenses

 

 

3,347

 

 

 

1,518

 

 

 

1,829

 

Net loss

 

$(30,450)

 

$(24,709 )

 

$(5,741)

 

 
3

Table of Contents

 

Revenue

 

During the three months ended September 30, 2022 and 2021, we did not generate any revenues from operations.

 

Operating Expenses

 

Operating expenses for the three months ended September 30, 2022 and 2021 were $27,103 and $23,191, respectively. For the three months ended September 30, 2022, operating expenses consisted of professional fees of $21,712, management fees-related party of $4,500, and general and administrative expenses of $891. For the three months ended September 30, 2021, operating expenses consisted of professional fees of $19,421, management fees -related party of $3,000, and general and administrative expenses of $770.

 

The increase in operating expenses is primarily the result of an increase in management fees -related party of $1,500 and professional fees of $2,291, as compared to the corresponding period in the prior year.

 

Other Expenses

 

For the three months ended September 30, 2022 and 2021, other expenses consisted of interest on promissory notes of $3,347 and $0, respectively, and interest on promissory note – related party of $0 and $1,518, respectively.

 

Net Loss

 

As a result of the foregoing, we incurred a net loss of $30,450 for the three months ended September 30, 2022, compared to a net loss of $24,709 for the three months ended September 30, 2021.

 

Nine Months Ended September 30, 2022, Compared to Nine Months Ended September 30, 2021

 

Our results of operations for the nine months ended September 30, 2022 and 2021 are summarized below:

 

 

 

 Nine Months Ended

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

2022

 

 

2021

 

 

Change

 

Revenue

 

$-

 

 

$-

 

 

$-

 

Operating expenses

 

 

85,410

 

 

 

134,248

 

 

 

(48,838)

Other expenses

 

 

8,589

 

 

 

4,606

 

 

 

3,983

 

Net loss

 

$(93,999)

 

$(138,854 )

 

$44,855

 

 

Revenue

 

During the nine months ended September 30, 2022 and 2021, we did not generate any revenues from operations.

 

Operating Expenses

 

Operating expenses for the nine months ended September 30, 2022 and 2021 were $85,410 and $134,248, respectively. For the nine months ended September 30, 2022, operating expenses consisted of professional fees of $72,135, management fees – related party of $10,500, and general and administrative expenses of $2,775. For the nine months ended September 30, 2021, operating expenses consisted of professional fees of $126,037, management fees -related party of $6,000, and general and administrative expenses of $2,211.

 

The decrease in operating expenses is primarily the result of a decrease in professional fees of $53,902, offset by an increase in management fees -related party of $ 4,500 , as compared to the corresponding period in the prior year.

 

 
4

Table of Contents

 

Other Expenses

 

For the nine months ended September 30, 2022 and 2021, other expenses consisted of interest on promissory notes of $5,432 and $2,250, respectively, and interest on promissory note – related party of $3,157 and $2,356, respectively.

 

Net Loss

 

As a result of the foregoing, we incurred a net loss of $93,999 for the nine months ended September 30, 2022, compared to a net loss of $138,854 for the nine months ended September 30, 2021.

 

Liquidity and Capital Resources

 

 

 

September 30,

 

 

December 31,

 

 

 

 

 

2022

 

 

2021

 

 

Change

 

Cash

 

$17,028

 

 

$2,266

 

 

$14,762

 

Total Assets

 

$17,028

 

 

$2,266

 

 

$14,762

 

Total Liabilities

 

$237,213

 

 

$129,952

 

 

$107,261

 

Stockholders’ Deficit

 

$(220,185)

 

$(127,686 )

 

$(92,499)

Working Capital Deficit

 

$(220,185)

 

$(127,686 )

 

$(92,499)

 

As of the date of this report, we had yet to generate any revenues from our business operations. 

 

As of September 30, 2022, we had current assets of $17,028, current liabilities of $237,213, and our working capital deficit was $220,185. The increase in working capital deficit during the nine months ended September 30, 2022, compared to nine months ended September 30, 2021, was mainly due to an increase in notes payable related to promissory notes issued to a third party of $235,000 and paid off promissory note - related party of $128,750, partially offset by an increase in cash of $14,762. We anticipate that our current liquidity is not sufficient to meet the obligations associated with being a company that is fully reporting with the SEC.

 

To date, we have managed to keep our monthly cash flow requirement low for two reasons. First, our sole officer draws only a nominal salary at this time. Second, we have been able to keep our operating expenses to a minimum by operating in space provided at no or nominal expense by our shareholders or consultants.

 

We currently have no external sources of liquidity such as arrangements with credit institutions or off-balance sheet arrangements that will have or are reasonably likely to have a current or future effect on our financial condition or immediate access to capital.

 

Our financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplates our continuation as a going concern. We have not yet generated any revenue and have incurred losses to date of $93,999. In addition, our current liabilities exceed our current assets by $220,185. These factors raise substantial doubt about our ability to continue operating as a going concern. Our ability to continue our operations as a going concern, realize the carrying value of our assets, and discharge our liabilities in the normal course of business is dependent upon our ability to raise capital sufficient to fund our commitments and ongoing losses, and ultimately generate profitable operations.

 

Cash Flows

 

 

 

 Nine Months Ended

 

 

 

September 30,

 

 

 

2022

 

 

2021

 

Cash used in operating activities

 

$(91,488)

 

$(99,971 )

Cash provided by Investing Activities

 

$-

 

 

$-

 

Cash provided by financing activities

 

$106,250

 

 

$115,000

 

Net Change in Cash

 

$14,762

 

 

$15,029

 

 

 
5

Table of Contents

 

Operating Activities

 

For the nine months ended September 30, 2022, net cash used in operating activities was $91,488, related to our net loss of $93,999, increased by a  decrease in accrued note payable interest -related party of $1,196 and reduced by an increase in  stock based compensation -related party of $1,500 and accounts payable and accrued liabilities of $2,207 .  For the nine months ended September 30, 2021, net cash used in operating activities was $99,971, related to our net loss of $138,854, increased by a decrease in accounts payable and accrued liabilities of $36,157 and reduced by an increase in expenses paid by related party of $74,184 and an increase in accrued interest payable to related party of $856.

 

Investing Activities

 

The Company did not use any funds for investing activities during the nine months ended September 30, 2022 and 2021.

 

Financing Activities

 

The Company provided $106,250 and $115,000 in financing activities during the nine months ended September 30, 2022 and 2021, respectively. During the nine months ended September 30, 2022, the Company received loan in the amount of $235,000 and loans from related parties in the aggregate amount of $54,500, and repaid the full outstanding principal notes - related parties of $183,250 and accrued interest payable – related party  of $4,352.  During the nine months ended September 30, 2021, the Company received a loan in the amount of $150,000, a loan from related party in the amount of $115,000 and repaid in full all outstanding principal loan of $150,000 and accrued interest of $2,250.

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As of September 30, 2022, the Company has reoccurring losses from operations, an accumulated deficit of $626,986 and has earned no revenues. The Company intends to fund operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending December 31, 2022.

 

The ability of the Company to emerge from the early stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of its business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings.

 

These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financial statements.

 

 
6

Table of Contents

 

Off-Balance Sheet Arrangements

 

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

 

Contractual Obligations

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

  

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) that are designed to ensure that information required to be disclosed in our Securities Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to our management, as appropriate, to allow timely decisions regarding required disclosure.

 

Our management has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, management has concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were not effective.

 

Changes in Internal Control over Financial Reporting

 

There has been no change in our internal control over financial reporting identified in connection with the evaluation we conducted on the effectiveness of our internal control over financial reporting as of September 30, 2022, that occurred during our third fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 
7

Table of Contents

 

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We know of no active or pending legal proceedings against us, nor are we involved as a plaintiff in any proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any beneficial shareholder are an adverse party or has a material interest adverse to us.

 

ITEM 1A. RISK FACTORS

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Other than as previously reported in our Current Reports on Form 8-K, we did not sell any other unregistered securities during the three-month period ended September 30, 2022, or subsequent period through the date hereof.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

 
8

Table of Contents

 

ITEM 6. EXHIBITS

 

The following exhibits are included as part of this report:

 

Exhibit No.

 

Description

 

31.1 / 31.2 *

 

Certification of Principal Executive Officer and Principal Accounting and Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act and Rule 13a-14(A) or 15d-14(A) under the Securities Exchange Act of 1934

 

32.1 / 32.2 *

 

Certification of Principal Executive Officer and Principal Accounting and Financial Officer pursuant to18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

101*

 

Inline XBRL Document Set for the financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q.

 

 

 

104*

 

Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.

_______

*Filed herewith

 

 
9

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

MED SPA VACATIONS INC.

 

 

 

 

 

Dated: October 21, 2022

By:

/s/ Irwin Schneidmill

 

 

Name:

Irwin Schneidmill

 

 

Title:

President, Treasurer and Secretary

(Principal Executive Officer and Principal Financial and Accounting Officer)

 

 

 
10

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
8/31/23
5/1/23
3/1/23
1/18/23
12/31/22
11/29/22
10/26/22
Filed on:10/21/22
For Period end:9/30/22
9/27/22
9/1/22
7/11/22
6/30/2210-Q
5/9/22
5/2/22
3/31/2210-Q
3/24/2210-K
3/1/22
2/11/22
1/18/22
12/31/2110-K
12/30/21
10/27/21
9/30/2110-Q
9/28/21
7/1/21
6/30/2110-Q,  8-K
6/18/21
5/21/21
5/10/218-K
3/31/2110-Q
2/12/218-K
2/4/218-K
12/31/2010-K
10/5/15
 List all Filings 
Top
Filing Submission 0001640334-22-002264   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 5:17:39.1am ET